Airocide to be Deployed in Pakistan Government Hospitals

Expands Global Footprint with Distribution Now in 52 Countries

Applied UV, Inc. (NasdaqCM: AUVI ) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced that it has expanded its global distribution reach with our distributor, M/S Novatek Pakistan being awarded as the sole source provider of Airocide air purification systems for government hospitals via a government tender for the KPK Province in Pakistan.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220609005149/en/

Applied UV's distribution partner, M/S Novatek Pakistan has extensive experience in dealing with the Pakistani government and previously won a similar government tender with the installation of 657 Airocide air purification systems installed throughout the country.

Mr. Munawwar Zahid, CEO of M/S Novatek Pakistan stated, "M/S Novatek Pakistan is proud to be the sole distributor of the Airocide Patented technology that was developed for NASA and is listed as an FDA Class II Medical device allowing us to deploy it throughout the country of Pakistan. We were selected to partner with Airocide because we knew that their air purification solutions are the best in the class, which have been deployed and used by globally recognized brands throughout the world to protect against SARS-COV-2 and other harmful air-borne pathogens even those too small to be filtered."

John Andrews, Applied UV's Chief Executive Officer stated, "We are proud to partner with M/S Novatek Pakistan and appreciate the trust they have placed in our Airocide suite of air purification solutions. Improving the quality of indoor air in all public indoor places, specifically government hospitals, protecting the facilities, staff and the patients who frequent them from dangerous pathogens is at the center of efforts by governments globally. With the implementation of these government guidelines and standards for business to use to improve indoor air quality beginning, our air purification solutions are the best-in-class tools to use as the world's economy begins to re-open, post pandemic. As a Company, we are very aware of the great importance of improving the circle of care by protecting the worlds front line healthcare providers post this three-year pandemic. We look forward to working with M/S Novatek, we are extremely confident that our air purification solutions will help them achieve their stated goals."

Mr. Zahid, further stated, "We are grateful for invaluable business relationship we share with Applied UV and for always standing by our side. The support, dedication, professionalism, and hard work of each member of Applied UV team, contributed greatly to the success of this mutual venture. Airocide is something of great value in Pakistan due to its filter-less technology and environment-friendly proprieties. We see a massive demand for Airocide in the coming year. We have enjoyed a very successful seven-year partnership and we are looking forward to many more."

Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works"). SteriLumen's Airocide® air purification devices are research backed, clinically proven and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photo-catalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities and homes. SteriLumen's connected platform for Data Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company's Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices' proximity. The Company's patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen intensive location.

For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/

The information contained herein may contain "forward-looking statements." Forward-looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward-looking statements are based on the Company's current expectations and assumptions regarding its business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220609005149/en/

For additional Company Information: Applied UV Inc. John F. Andrews Applied UV Inc., CEO & Director john.andrews@applieduvinc.com

Contact: Brett Maas, Managing Principal Hayden IR brett@haydenir.com (646) 536-7331

News Provided by Business Wire via QuoteMedia

Back in 2001, the National Human Activity Pattern Survey by the United States Environmental Protection Agency already stated that Americans spend around 90 percent of their time indoors. Author and Stanford University Professor Wayne Ott studied this data from 12 western countries and concluded, “The finding that emerges is that we are basically an indoor species.”

Fast forward to 2020 and the world is hit by a pandemic caused by a highly transmissible, airborne virus that reinforces the need for safe and effective sanitizing solutions to protect facilities, employees and consumers.

Indoor air quality has become an even more important issue as world economies start the recovery process. In 2021, 39 scientists reiterated the need for a "paradigm shift" and called for improvements in, "how we view and address the transmission of respiratory infections to protect against unnecessary suffering and economic losses."

In addition to this, the global air purifier market size is set to grow exponentially. It was valued at USD 9.24 billion back in 2021 and is predicted to hit around USD 22.84 billion by 2030. According to Precedence Research, the immense demand for air purification and sterilization in the US will be driven by the commercial sector.

Applied UV (NASDAQ:AUVI, AUVIP) is poised to benefit from both increased awareness and commercial demand. The company is focused on innovating new products to combat infections with products covering both airborne particles and surface sterilization and designed for a variety of industries, including healthcare, hospitality and other commercial applications.

The union of these companies has helped ensure the success of both ventures. “By joining forces, we can distribute a combined catalog of SteriLumen and Airocide® products through the Applied UV supply chain and accelerate deal flow in the hospitality, hotel, cruise ship, health care, nursing home, grocery, wine, commercial building and retail sectors,” said Applied UV Interim CEO & Director Max Munn in an interview with INN.

SteriLumen’s products do not create byproducts as HEPA filtration systems do and are independently tested to ensure they are continually effective against COVID-19 variants and other harmful pathogens. SteriLumen’s line of products attack harmful in the air, and pathogens on surfaces, plus the SteriLumen app for asset management that provides data-driven disinfection insights.

A strong management team leads Applied UV with experience in R&D, corporate finance, and various healthcare sectors, providing a stable foundation for the company to scale and grow. Interim CEO and Director Max Munn, Mike Riccio Chief Financial Officer, Interim Chief Operating Officer John Hayman III and Chairman Joel Kanter are respected in their specialties and have already demonstrated their expertise by building Applied UV to where it is today.

Airocide® was originally developed for NASA by the University of Wisconsin, and was named a 2014 Gold Edison Award Winner. Has been featured on a number of media such as Fox News, CNN, Maxim and others. Airborne pathogens are a major problem and these two products attack them head-on.

ScientificAir is a larger unit for use in commercial spaces, like venues, airports and nursing homes. Meanwhile, Airocide® is designed for smaller rooms where aesthetics matter. Both products produce no harmful byproducts and are designed to produce safe, clean air.

Lumicide™ has two products that use similar UV technology to attack harmful pathogens on surfaces. The Lumicide™ Ribbon is a long UV light designed to sterilize surfaces and is the only known UVC solution ETL certified for safe operation while people are present in the room. The Lumicide™ Drain complements the Lumicide™ Ribbon and disinfects sinks and drains. Independent scientific not-for-profit testing laboratory CUBRC, Inc., confirmed that the SteriLumen Lumicide™ Ribbon kills SARS-CoV-2 (COVID-19 Virus).

Every modern system should have a dashboard for easy monitoring and asset management, so Applied UV created SteriLumen App to manage all Applied UV devices, including providing smart management and essential reporting solutions.

John F. Andrews has over 30 years of senior leadership experience in telecom and technology companies, both public and private. He has been CEO of several public companies as well as started and founded companies from ground zero. His experience includes leading three (3) companies to strategic exits (two (2) private and one (1) public), raising over one hundred (100) million dollars of public and private capital, managing numerous mergers and acquisitions, leading companies through explosive growth as well as rightsizing, and being recruited to turn around stalled companies. He recently was the CEO and Co-founder of Trinity IT Services LLC and CEO of TrekSecure LLC. A seasoned executive, his experience also includes being Chairman and EVP of ShipXpress which GE acquired, being CEO of Giga (NASDAQ GIGA) where he led the company's sale to Forrester Research (NASDAQ FORR) and being the CEO of e-Medsoft which went public. His fortune 300 corporate experience includes being CIO and SVP of CSX Transportation at CSX (NASDAQ CSX) corporation managing thousands of employees. During his tenure at CSX, he was credited in achieving over five hundred (500) million dollars in operating expense reductions through his visionary and portfolio technology projects. As CIO he received several industry awards to include CIO of the year from Information Week and top industry visionary from Computerworld. While at CSX, Andrews also consulted with Sun Microsystems (NASDAQ SUNW) on the development of JAVA. Prior to CSX Andrews held executive positions with telecom giant GTE, to include division CIO, President Government Information Systems and President Healthcare Information Systems. Andrews has an MBA from the University of Puget-Sound, Seattle WA, and a BA, Business Administration and Finance from Whitworth University, Spokane WA.

Max Munn has held this position at Munn Works for over 20 years. Munn is also Co-chairman of Dieu Donne Inc., a not-for-profit and a leading, world-recognized atelier wherein dimensional, handmade paper is utilized in the making of art. Munn attended MIT from 1961-to 1966, majored in chemistry and architecture; and received a Bachelor of Architecture degree. Munn also attended Columbia University for post-graduate studies from 1966-1968, working toward a Ph.D. in architectural history.

Mr. Riccio is a highly accomplished CFO who brings an extensive array of financial experience to Applied UV, including a background with global public companies in corporate finance, operations management systems, and corporate M&A planning and integration. Riccio joins Applied UV to oversee the company's finance team reporting directly to the Chief Executive Officer.

John Hayman served as Kes Science’s President and CEO for 18 years leading the company’s growth, R&D and new product development. Before Kes, Hayman was an accountant where he earned his COA Certification and ended his tenure as a Certified Public Account with KMPG.

Joel Kanter has served as President of Windy City, Inc., a privately-held investment firm, since July 1986. From 1989 to November 1999, Kanter served as the President, and subsequently as the President and Chief Executive Officer of Walnut Financial Services, Inc., a publicly-traded company (NASDAQ:WNUT).

Monica Woo is a seasoned Fortune 100 Executive and Board member with many years of accomplished experience and is known for her strategic insights and contributions serving in C-suite level positions on numerous Companies; her ability to position new and existing companies for long-term success and her extensive national and international network of senior-level contacts in business, government, and nonprofits will be extremely valuable to Applied UV's growth. Monica Woo's distinguished career brings Applied UV a strong track record in delivering profitable growth for multi-national globally recognized B2B and B2C eCommerce, food & beverage, investment banking and technology companies, including: the former President of 1-800-Flowers.Com, Inc., flagship Consumer Floral Division, the former Chief Revenue & Strategy Officer of FreshDirect (Ahold Delhaize), the former President of Bacardi Global Brands, the former Chief Marketing Officer of Diageo PLC Europe, former Executive Vice President of Nutrisystem's, the former Chief Marketing and Strategy Officer, Deutsch Bank's Online-LATAM, Sao Paulo, Brazil/NY, NY and the former Chief Marketing Officer Citibank Online & Citibank Private Bank. Monica Woo holds an MBA from the Wharton School of Business, University of Pennsylvania.

Restructure to Divest of an Estimated $5M in Liabilities and Annual Operating Expenses and to Reposition DGTL Holdings Inc. for Scalable Revenue Growth, Cashflow Positivity and Accretive M&A

The DGTL Holdings Inc. (TSXV: DGTL) ("DGTL" or the "Company") board of directors reports that the Company has initiated a strategic restructuring of its wholly owned subsidiaries, Hashoff LLC ("Hashoff"") and Engagement Labs Inc. ("Engagement Labs"). The goal of restructuring its subsidiaries is to apply objective third-party financial analysis to current business operations to assess long term viability and to optimize organizational structures. The result of this initiative is an estimated divestiture of $5,000,402[i] in liabilities and operating expenses and a repositioning of the Company for scalable revenue growth, near-term cashflow positivity, and long-term shareholder equity.

On June 1, 2022, Hashoff LLC retained the services of Lindenwood Associates, a New York based strategic development and restructuring firm ("Lindenwood") to assess legal and financial viability as well as Klestadt Winters Jureller Southard & Stevens, LLP ("KWJSS") to provide legal services to Hashoff LLC in connection therewith. The Hashoff LLC restructuring team has completed a thorough and objective viability assessment. After presenting their report, and reviewing the facts, the board voted unanimously to accept the recommendations of Lindenwood to commence a formal orderly wind down and subsequent dissolution of Hashoff LLC in accordance with Section 18-801 of the Delaware Limited Liability Company Act.

The result of the Hashoff LLC wind down is the divestiture of an estimated $1,939,053 in accounts payable and accrued expenses and $572,849 in contingent liabilities from the DGTL Holdings Inc. consolidated balance sheet.[ii] As the initial step towards this financial restructuring project, both of DGTL's wholly owned subsidiaries have been approved for PPP (Paycheck Protection Program) loan forgiveness. PPP loan forgiveness applications were processed by the SBA (Small Business Association) a US federal administration agency that administers small business relief loans (as authorized by s.1106 of the federal CARES Act). Hashoff LLC had $177,000 in PPP loans forgiven and Engagement Labs had $420,000 in loans forgiven totalling $597,000 in interest bearing loans removed from the DGTL Holdings balance sheet.

In addition, by identifying and implementing numerous cost savings and efficiency measures, the new DGTL executive team has produced a 50% reduction in annual operating expenses for Engagement Labs Inc. The financial restructure of Engagement Labs provides a viable entity which will now serve as DGTL's flagship social media subsidiary, with multiple operating business lines. In doing so, Engagement Labs Inc. will expand product and service offerings to include strategy, execution, measurement and distribution solutions to serve DGTL's Fortune 100 clients as a full-service social media PaaS (Platform-as-a-Service).

Therefore, within the first 120 days under the leadership of the new DGTL executive team, the Company has proactively divested over $3,234,743 in current and non-current liabilities and an additional $1,891,500 in annual operating expenses[iii] totalling an estimated first year reduction of $5,000,402 in long term debt and on-going operating expenses. When accounting for the longer-term impact of the significant reduction in annual operating expenses, a continuance of the previous cost structure would continue to increase this total estimate with every future year of on-going operations. Financial improvements will begin to be reflected within the Q1 2023 financial statements (October 30, 2022), and subsequent filings, thereafter.

In summary, the new DGTL executive team is dedicated to restoring fiscal responsibility, accountability and sound corporate governance in order to maximize long term value of shareholder equity. Reducing liabilities and post-restructure operating expenses by an estimated $5,000,402 is a major material improvement to the consolidated financial position of the Company. Moving forward, DGTL is now positioned for scalable revenue growth and accretive M&A with a stronger corporate structure and a viable financial position.

In closing, DGTL will be hosting a video webinar on Wednesday July 6th, 2022, which will include a CEO update on the Company and its current operations and future business interests. The participant details for this meeting are listed below. Availability is limited. Register in advance to secure participation.

DGTL CEO Update July 6th, 2022, 01:00 PM Eastern Time (US and Canada)

Register in advance for this meeting via the link below. https://zoom.us/meeting/register/tJYpdO2tpjkrE9SXqxzeWGtson8BaIOSH3LK

After registering, you will receive a confirmation email containing information about joining the meeting.

For more information, please contact:

DGTL Holdings Inc. John David A. Belfontaine Chief Executive Officer, Chairman

Email: IR@dgtlinc.com Phone: +1 (877) 879-3485

DGTL Holdings Inc. acquires and accelerates transformative digital media, marketing and advertising software and services companies. DGTL (i.e. Digital Growth Technologies and Licensing) specializes in accelerating fully commercialized enterprise level SaaS (software-as-a service) and PaaS (Platform-as-a-Service) companies entering a rapid growth stage within the sectors of social media, gaming, streaming, OTT and others. In doing so, DGTL is seeking to build full-service operating business lines in each sector complete with content, analytics and distribution solutions. DGTL is seeking new accretive M&A opportunities via a blend of unique capitalization structures. DGTL Holdings Inc. is traded on the Toronto Venture Exchange as "DGTL", the OTCQB exchange as "DGTHF", and the FSE as "A2QB0L". DGTL Holdings Inc. has 44,549,265 common shares issued and outstanding, as of the date of this release. For more information visit: www.dgtlinc.com.

As a wholly owned subsidiary of DGTL Holdings Inc., Engagement Labs is an industry-leading data and analytics firm that provides social intelligence for Fortune 500 brands and companies. Engagement Labs' TotalSocial® platform focuses on the entire social ecosystem by combining powerful online (social media) and offline (word of mouth) data with predictive analytics. Engagement Labs has a proprietary ten-year database of unique brand, industry and competitive intelligence, matched with its cutting-edge predictive analytics that use machine learning and artificial intelligence to reveal the social metrics that increase marketing ROI and top line revenue for its diverse group of enterprise level clients. Engagement Labs Inc. will expand product and service offerings to include strategy, execution, measurement and distribution solutions to serve DGTL's Fortune 100 clients as a full-service social media PaaS (Platform-as-a-Service).

To learn more visit www.engagementlabs.com.

Lindenwood Associates is an experienced strategic development and restructuring firm. Lindenwood is led by corporate turnaround and restructuring specialists with progressive expertise leading and managing distressed companies, delivering results in crisis situations, divestitures, and a wide range of corporate development initiatives. Lindenwood leads companies through complex challenges spanning a diverse range of industries to achieve improved strength, value, and growth.

For more information visit https://www.lindenwoodassociates.com.

Klestadt Winters Jureller Southard & Stevens (KWJS&S), LLP is a boutique commercial law firm dedicated to providing superior legal services. The firm specializes in the primary areas of practice Corporate Reorganization and Restructuring, Commercial Litigation, Transactions & Finance.

For more information, please visit https://klestadt.com.

This news release contains certain statements that constitute forward-looking statements as they relate to DGTL and its subsidiaries. Forward-looking statements are not historical facts but represent management's current expectation of future events, and can be identified by words such as "believe", "expects", "will", "intends", "plans", "projects", "anticipates", "estimates", "continues" and similar expressions. Although management believes that the expectations represented in such forward-looking statements are accurate, there can be no assurance that they will prove to be correct. By their nature, forward-looking statements include assumptions, and are subject to inherent risks and uncertainties that could cause actual future results, conditions, actions or events to differ materially from those in the forward-looking statements. If and when forward-looking statements are set out in this new release, DGTL will also set out the material risk factors or assumptions used to develop the forward-looking statements. Except as expressly required by applicable securities laws, DGTL assumes no obligation to update or revise any forward-looking statements. The future outcomes that relate to forward-looking statements may be influenced by many factors, including but not limited to the impact of all intangible and variable economic and legal risks that at this time are immeasurable and impossible to define.

[i] All currencies in Canadian dollars and foreign exchange rates applied as of the date of this release. [ii] Hashoff LLC Current and non-current liabilities based on the Q3 2022 financials filed April 29, 2022, now available at SEDAR.com [iii] Due to the reduction in senior executive, employment and consulting wages from the board downsizing of management personnel

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/129799

News Provided by Newsfile via QuoteMedia

Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N) (TSXV:NSP) (OTC PINK:NSPDF) announces its audited financial results for the year ended December 31, 2021. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards

Naturally Splendid Chief Financial Officer Mr. George Ragogna states, "The company continues to focus on reducing operating overheads while we continue to re-purpose our existing certified food facility in Pitt Meadows, BC to optimize production of plant-based entrees. We have made positive strides for the Company in several areas including securing an exclusive ten (10) year manufacturing and distribution agreement for Canada with Flexitarian Foods Pty. Ltd, Australia's largest plant-based manufacturer. This 10-year exclusive manufacturing agreement can be extended for a further ten (10) year period.

The facility build-out will allow for the production of up to twenty (20) tons of plant-based entrees daily for the majority of our standard plant-based offerings, but as much as thirty (30) tons of plant-based production daily for certain products. This translates to a manufacturing capacity potential of over $30,000,000 CDN annually. Our manufacturing facility remains a cornerstone to the future of the Company as we expect to drive revenue from not only our Company branded products, but also through private label and contract manufacturing clients.

Ragogna continues, "The Company is focused on penetrating the plant-based market both in food service and retail channels. Initially, the Company focused on food service, developing a network of distributors that include national distribution partners such as Sysco Canada and Gordon Food Services (GFS). The Company recently engaged one of Canada's leading foodservice brokers, Tri-Elite Marketing to represent PlanteinTM across Canada. Food service was our initial focus, producing successes such as a national listing for our plant-based nuggets and tenders with Denny's Canada and Bar One restaurants".

The Company recently launched PlanteinTM, the Company's retail line of plant-based entrees. In this regard, the Company has secured exclusive rights for the PlanteinTM trademark for Canada from Flexitarian Foods. The term for licensing the PlanteinTM trademark is for ten (10) years with a ten (10) year renewal option, matching the term of the exclusive manufacturing and distribution agreement from Flexitarian Foods. Our initial PlanteinTM launch focuses on eight (8) plant-based entrees including a plant-based; Burger; Crispy Burger; Crumbed Tenders; Sweet Chili Tenders; Nuggets; Schnitzel (cutlet); Garlic Kiev; and the Phishy Fillet.

While we continue to progress with the build-out of our facility, our combination of brokers, distributors and internal sales staff continues to work towards increasing our sales in both food service and retail channels. All manufacturing equipment has been ordered, however, continued supply chain issues have delayed shipment of certain components of the manufacturing line which is pushing out the completion date of the facility. As such we have taken proactive measures with our strategic partners, Flexitarian Foods, and have ordered additional containers of product to support our aggressive sales strategy."

Company CEO Mr. Craig Goodwin states, "The Company recently attended three (3) significant industry tradeshows that have been on a hiatus for the past two (2) years due to the pandemic. Being able to sample our delicious entrees in tradeshow settings has made a huge difference, generating significant interest in our PlanteinTM line of plant-based offerings. Tradeshows attended include; Western Canada's largest natural, health and organics trade event, Canadian Health Food Association (CHFA) tradeshow; Grocery & Specialty Food West, Canada's leading western grocery trade fair; and the Planted Expo, Canada's largest plant-based consumer event of the year. These shows affirmed our belief that we have a winning product line and we have seen an increase in sales activity from retailers, food service outlets as well as consumers buying directly through the PlanteinTM website (www.plantein.ca).

Ragogna concludes, "The Company continues to make plant-based food manufacturing our priority. We firmly believe that the plant-based category has a bright future and as a manufacturer, we are well positioned to penetrate this market. Senior management is reviewing all operations and continues to create and execute a detailed strategic plan that focusses our attention on our core plant-based manufacturing business while reducing or eliminating operations that are not contributing to the growth of the Company".

During this reporting period, Covid-19 uncertainty negatively affected sales of existing product lines as well as impaired launches of new product lines. On March 11, 2020, the World Health Organization declared the outbreak of the novel coronavirus ("COVID-19") a global pandemic resulting in governments worldwide, including the Canadian government, to enact extensive measures in an effort to limit the spread of the virus. These measures, which include social distancing, travel restrictions, outright travel bans, and closures of non-essential businesses including restaurants, created a challenging period for the Company.Naturally Splendid recorded a net loss and comprehensive loss of $3,269,452 for the year ended December 31, 2021, compared with a net loss of $4,659,642 during the year ended December 31, 2020. The decrease in net loss and comprehensive loss was attributed to the decrease in selling and distribution expenses.

Gross profit margins increased by 3.4 percent of sales in the year ended December 31, 2021, compared with the year ended December 31, 2020. This is due to the increased profit margins in the new plant-based sales. The company's sales decreased by approximately $812,600 from the comparative period. During the year ended December 31, 2021, selling and distribution expenses decreased by approximately $560,000 largely due to a decrease in production (facility costs, quality assurance and lab testing) and production wages, which were offset by the government wage subsidy received during the year. Administrative expenses decreased by approximately $896,000 predominantly from corporate promotions and share-based payments. The decrease was attributed to a reduction in investor relations activity and the reduction of share-based payments.

Naturally Splendid recorded sales of $763,796 during the year ended December 31, 2021, compared with $1,576,408 for the year ended December 31, 2020.

The Company's sales decreased by approximately $813,000 from the comparative period. The Company had decreased sales in its private-label bars and bites business by approximately $790,000 and other branded products decreased by approximately $5,000. Branded hemp products decreased by approximately $65,000 and its new Natera Sport products decreased by approximately $149,000. The Company had sales of approximately $211,000 in its new Plant-based products.

During the year ended December 31, 2021, selling and distribution expenses decreased by approximately $560,000 largely due to a decrease in production (facility costs, quality assurance, lab testing and reduced production) and production wages which were offset by the government wage subsidy received during the quarter. Administrative expenses decreased by approximately $896,000 mainly from share-based payments and corporate promotions. The decrease was attributed to a reductionin investor relationsactivity due to the pandemicand the reduction of corporate salaries from the government wage subsidy.

The cost of sales during the year ended December 31, 2021, and 2020, were $681,615 and $1,576,408 respectively. The company gross margin percentage was 10.8 percent of sales during the year ended December 31, 2021.

The company continued its sales mix with exports of bulk seeds and launching its new plant-based products. The bulk hemp seeds sold at a lower gross margin percentage than compared with the plant-based products and private label sales. The company will continue to focus on its higher-margin products and new commercial opportunities. Gross profits for the year ended December 31, 2021, were $82,181 (11 percent of sales) compared with $142,930 (7 percent of sales) for the year ended December 31, 2020.

For the Year Ended December 31, 2021

For the Year Ended December 31, 2020

Basic and Diluted Earnings (Loss)

About Naturally Splendid Enterprises Ltd.

Founded in 2010, NSE operates a food manufacturing facility just outside Vancouver, BC in Canada. The Company has established numerous healthy, functional foods under recognized brands such as Natera Sport™, Natera Hemp Foods, CHII, Elevate Me™ and Woods Wild Bar™, and most recently Natera Plant Based Foods, a line of delicious plant-based meat alternatives for the rapidly growing plant-based market segment. The Company has a myriad of new products and line extensions under development that are approaching launch. NSE, through its joint venture Plasm Pharmaceutical, has been approved for conducting a phase 2 clinical trial approved by Health Canada for treatment of COVID-19. NSE has also developed proprietary technologies for the extraction of high-demand, healthy omega 3 and 6 oils from hemp.

NSE contract manufacturers for healthy, functional food products and ingredients focusing on plant-based ingredients. The Company provides contract manufacturing services for many healthy food companies, private labeling a wide variety of nutritional food products destined for global healthy food markets.

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-570-0902 (ext. 101)

On Behalf of the Board of Directors

Mr. J. Craig Goodwin CEO, Director

Naturally Splendid Enterprises Ltd. (NSP - TSX Venture; NSPDF - OTCQB; 50N - Frankfurt) #108-19100 Airport Way Pitt Meadows, BC, V3Y 0E2 Office: (604) 570-0902 Fax: (604) 465-1128 E-mail : info@naturallysplendid.com Website: www.naturallysplendid.com

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid's control including, Naturally Splendid's ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: Naturally Splendid Enterprises Ltd.

News Provided by ACCESSWIRE via QuoteMedia

Billy Goat Brands Ltd. (the " Company " or " Billy Goat Brands ") (CSE: GOAT), an investment issuer focused on investing in high-potential companies operating in the food technology sector, is pleased to announce it has entered into a non-binding Letter of Intent (the " LOI ") dated June 30, 2022 with Kojo Pet Performance Inc. (" Kojo ").

The LOI contemplates a Proposed Transaction, whereby the Company would acquire all issued and outstanding securities of Kojo by way of a share exchange agreement. Kojo is an innovative pet-food brand focused on producing and marketing plant and cell-based pet food offerings.

Pursuant to the proposed transaction, the Company will issue common share in its capital to the holders of common shares in the capital of Kojo (the " Consideration Shares ") at a deemed price per consideration share at a deemed price per Consideration Share equal to the minimum price allowed pursuant to the policies of the Canadian Securities Exchange, representing aggregate consideration to be determined and mutually agreed upon by the parties with reference to a pending valuation of Kojo, expected to be in the range of $500,000 to $1,000,000.

Additional shares may be issuable to the shareholders of Kojo, subject to the fulfillment of certain performance milestones being completed within 36 months from the closing date of the Proposed Transaction (the " Milestone Payments ").

The Proposed Transaction will be completed pursuant to available prospectus exemptions in accordance with applicable securities legislation. The Company and Kojo have agreed to negotiate in good faith the terms of a definitive agreement with respect to the proposed transaction within 60 days from the LOI.

The Proposed Transaction is subject to receipt of all necessary regulatory approvals, including, as applicable, approval of the CSE, completion of due diligence reasonable or customary in a transaction of a similar nature, and entering into a definitive agreement, among other conditions. The proposed transaction would be an arm's-length transaction for the company and would not constitute a fundamental change or result in a change of control of the company, within the meaning of the policies of the CSE.

The Company also announces that Tony Harris has resigned as Chief Executive Officer and Director effective immediately. Billy Goat Brands would like to thank Mr. Harris for his many contributions to the company and wishes him well with his future endeavours. Lawrence Hay, director of the Company will assume the role of Chief Executive Officer.

Billy Goat Brands is an investment issuer focused on investing in high-potential companies operating in the food technology sector.

For more information about the Company, please visit https://billygoatbrands.com/. The Company's final prospectus, financial statements and management's discussion and analysis, among other documents, are all available on its profile page on SEDAR at www.sedar.com .

The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING "FORWARD-LOOKING" INFORMATION

This news release contains certain forward-looking statements within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. The Company has provided the forward-looking statements in reliance on assumptions that it believes are reasonable at this time. All such forward-looking statements involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company's control. Such risks and uncertainties include, without limitation, delays resulting from or inability to obtain required regulatory approval. The reader is cautioned that the assumptions used in the preparation of the forward-looking statements may prove to be incorrect and the actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do, what benefits, including the amount of proceeds, the Company will derive therefrom. Readers are cautioned that the foregoing list of factors is not exhaustive. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Lawrence Hay, Director Billy Goat Brands Ltd. Email: info@billygoatbrands.com Phone: +1 (604) 687-2038

News Provided by GlobeNewswire via QuoteMedia

 Greenlane Renewables Inc. ("Greenlane") (TSX: GRN) (FSE: 52G) is pleased to announce that it has hired Monty R. Balderston to be Chief Financial Officer, effective July 18 2022.

Mr. Balderston joins Greenlane with over 25 years of experience in progressively senior financial leadership positions, including the role of Chief Financial Officer, in both public and private companies spanning mechanical equipment provisioning and installation, civil construction, industrial supply, maintenance services, and diversified energy services. He is a Chartered Professional Accountant and holds a Bachelor of Commerce degree from the University of Alberta . Mr. Balderston began his career at PricewaterhouseCoopers LLP and for the last five years was the Chief Financial Officer with Mosaic Capital Corporation where he oversaw all financial reporting processes and strategic planning, including budgeting, forecasting and acquisitions.

"We are excited to have Monty join the Greenlane team, as he brings an extensive background in corporate finance and senior executive leadership," said Brad Douville , President and Chief Executive Officer. "His background in senior finance and accounting roles, including capital markets experience with equity and debt financings, as well as mergers and acquisitions, will add significant value not only to our team but to our shareholders as well."

Lynda Freeman , the Company's current Chief Financial Officer, who is resigning from the post to spend more time with her young family, will remain in her position until Mr. Balderston's appointment. Following his appointment, Ms. Freeman will continue with Greenlane on a part-time basis in an alternate role, ensuring a seamless transition. "I would also like to thank Ms. Freeman for her dedication and professionalism and we wish her all the best as she shifts her focus to family," said Mr. Douville.

Greenlane Renewables is a pioneer in the rapidly growing renewable natural gas ("RNG") industry. As a leading global provider of biogas upgrading systems, we are helping to clean up two of the largest and most difficult-to-decarbonize sectors of the global energy system: the natural gas grid and the commercial transportation sector. Our systems produce clean, low-carbon and carbon-negative RNG from organic waste sources such as landfills, wastewater treatment plants, dairy farms, and food waste streams. To the company's knowledge,  Greenlane is the only biogas upgrading company offering the three main technologies: waterwash, pressure swing adsorption, and membrane separation. Greenlane's business has been built on over 30 years of industry experience, patented and proprietary technology, over 100 hydrogen sulfide treatment systems sold, and over 135 biogas upgrading systems sold into 19 countries, including some of the largest RNG production facilities in the world. For further information, please visit www.greenlanerenewables. com .

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2022/30/c6426.html

News Provided by Canada Newswire via QuoteMedia

dynaCERT Inc. (TSX: DYA) (OTCQB: DYFSF) (FRA: DMJ) (" dynaCERT " or the "Company") is pleased to announce the results of the annual and special meeting of its shareholders, which was completed today (the "Meeting"). The Meeting was held virtually via TSX Trust Company's virtual meeting platform. A total of 107,783,677 common shares of the Company (each, a "Common Share"), representing 28.25 % of the total Common Shares outstanding, were represented in person or by proxy at the Meeting. dynaCERT 's shareholders voted in favor of all items of business put forward at the Meeting, being the election of all nominated directors and the re‐appointment of BDO Canada LLP as the auditors of the Company.

The votes in respect of each of these items were held via ballot, the results of which were as follows:

Description of Matter Voted Upon

1. Amendment to resolution fixing the number of directors from seven (7) to five (5)

2. Ordinary resolution fixing the number of directors at five (5)

3. Ordinary resolution approving the election of the following nominees as directors of the Corporation

4. Ordinary resolution approving the appointment of BDO Canada LLP as auditors of the Corporation

On April 4, 2022, the Company announced that the Company's audit committee had engaged independent legal counsel to assist them in examining the validity, legal standing, enforceability, and potential future recoverability of certain related party and other transactions as disclosed in note 24 of the Company's audited financial statements in respect of the financial year ended December 31, 2021. The review by the Audit Committee is now complete and the following is a summary of some of the findings and conclusions of the review. The Audit Committee, in consultation with its independent counsel, conducted a detailed review of each of the items referenced in the aforementioned note 24. This process included reviews of all documents, communications, correspondence, resolutions and supporting materials relating to each item, in addition to conversations between the Audit Committee's counsel and members of the Company's management. The Company is reporting on the following salient points from the Audit Committee's findings:

Having reviewed the Audit Committee's findings at the Board level, the Company has noted certain procedural errors in connection with some of the transactions reviewed and has concluded that certain weaknesses in the Company's internal controls have become apparent. These include the following:

Having reviewed the findings of the Audit Committee and considering the internal control weaknesses noted thereby, the Company has adopted the following remedial measures:

dyna CERT Inc. manufactures and distributes Carbon Emission Reduction Technology for use with internal combustion engines. As part of the growing global hydrogen economy, our patented technology creates hydrogen and oxygen on-demand through a unique electrolysis system and supplies these gases through the air intake to enhance combustion, resulting in lower carbon emissions and greater fuel efficiency. Our technology is designed for use with many types and sizes of diesel engines used in on-road vehicles, refrigerated trailers, off-road construction, power generation, mining and forestry equipment, marine vessels and railroad locomotives. Website: www.dynaCERT.com .

Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. In particular, forward-looking information in this press release includes, but is not limited to the remedial steps outlined following the review of certain transactions by the Company's audit committee. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance of achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; the uncertainty of the emerging hydrogen economy; including the hydrogen economy moving at a pace not anticipated; our ability to secure and maintain strategic relationships and distribution agreements; and the other risk factors disclosed under our profile on SEDAR at www.sedar.com . Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Neither The Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the The Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of the release.

On Behalf of the Board

View source version on businesswire.com: https://www.businesswire.com/news/home/20220629006037/en/

Jim Payne, CEO & President dynaCERT Inc. #101 – 501 Alliance Avenue Toronto, Ontario M6N 2J1 +1 (416) 766-9691 x 2 jpayne@ dynaCERT .com Investor Relations dynaCERT Inc. Nancy Massicotte +1 (416) 766-9691 x 1 nmassicotte@ dynaCERT .com

News Provided by Business Wire via QuoteMedia

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, today announced a research collaboration agreement with Harvard Medical School in support of a project led by Joan S. Brugge, PhD, a faculty member. The project aims to discover new targets that may lead to the development of novel anti-cancer treatments.

The research collaboration will focus on the discovery and development of novel targets to enhance tumor cell responsiveness to chemotherapy and immunotherapies in specific cancers including lung, head and neck, cervical, and bladder cancers. The research team at Harvard Medical School is led by Joan S. Brugge, PhD, who is the Louise Foote Pfeiffer Professor of Cell Biology and Co-Director of the Ludwig Cancer Center.

"We are grateful for the opportunity to work with Prof. Brugge and her expert team at Harvard Medical School to advance discovery in oncology," stated Dr. Miguel Lopez-Lago, BriaCell's Chief Scientific Officer. "We are hopeful that insights from this effort may potentially inform BriaCell's future R&D aims in developing novel anti-cancer drugs. This research collaboration is in line with our overall strategy of developing safe and effective treatments for cancer patients with large unmet medical needs."

"Scientists have made tremendous strides in understanding the basic biology of cancer over the last decade. Despite this formidable progress, persistent challenges remain in translating these discoveries into effective and safe precision-targeted cancer treatments," stated Brugge. "Our work aims to solve these challenges."

BriaCell will have the option to negotiate a license to innovations owned by Harvard University that arise under the one-year collaboration. The research agreement was coordinated by Harvard's Office of Technology Development.

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/ .

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Examples of forward-looking statements in this news release include, among others, statements that the Company makes regarding the potential for discovering and developing new targets that may lead to the development of novel anti-cancer treatments. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov . Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Company Contact: William V. Williams, MD President & CEO 1-888-485-6340 info@briacell.com

Media Relations: Jules Abraham Director of Public Relations CORE IR 917-885-7378 julesa@coreir.com

Investor Relations Contact: CORE IR investors@briacell.com

News Provided by GlobeNewswire via QuoteMedia

Investing News Network websites or approved third-party tools use cookies. Please refer to the  cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.